Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | CDK7 | P50613 | 6/20 | 0.41 |
| ▸ | CCNH | P51946 | 6/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.41 |
| ▸ | CCNK | O75909 | 4/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443814 | 0.80 | HDAC8 (0.59) | HDAC8ROCK2 | |
| SCHEMBL445296 | 0.78 | HDAC8 (0.50) | HDAC8 | |
| SCHEMBL445407 | 0.78 | HDAC8 (0.50) | HDAC8 | |
| SCHEMBL444174 | 0.77 | HDAC8 (0.57) | HDAC8PTGDR2SYK | |
| SCHEMBL443193 | 0.76 | HDAC8 (0.63) | HDAC8 | |
| SCHEMBL447618 | 0.75 | HDAC8 (0.60) | HDAC8 | |
| SCHEMBL444459 | 0.75 | HDAC8 (0.60) | HDAC8 | |
| SCHEMBL447623 | 0.75 | HDAC8 (1.00) | HDAC8 | |
| SCHEMBL444360 | 0.75 | HDAC8 (0.58) | HDAC8 | |
| SCHEMBL444892 | 0.74 | HDAC8 (0.64) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | claimed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | claimed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | HDAC8 304/4885ROCK2 2370/4885PTGDR2 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.